Vir Biotechnology and Gilead Sciences launch exclusive partnership to develop three PRO‑XTEN masked T‑cell engagers
Vir Biotechnology and Gilead Sciences announced a collaboration to discover, design and optimize three dual‑masked T‑cell engager candidates for solid‑tumor cancers using Vir’s PRO‑XTEN platform. Vir will conduct the discovery work while Gilead receives an exclusive license to develop, manufacture and commercialize the candidates. The agreement includes an upfront cash and equity payment to Vir and milestone payments that could total up to $1.74 billion.
Why it matters
Vir’s shares jumped roughly 10% in pre‑market trading as investors priced in the cash infusion and future milestone upside. Gilead adds three potential oncology assets to its pipeline, expanding its immunotherapy portfolio.
Key facts
- 1Vir will handle discovery, design and optimization of three PRO‑XTEN dual‑masked T‑cell engager candidates, and Gilead will receive an exclusive license to develop and commercialize them. investing.com
- 2The agreement provides Vir with an upfront cash component of $65 million and a $25 million equity investment at a 30 % premium. investing.com
- 3Vir will be eligible to receive up to $45 million in near‑term preclinical milestones. investing.com
- 4Potential additional payments under the deal could total up to $1.74 billion in development, regulatory and commercial milestones, plus tiered royalties on net sales. investing.com
- 5Vir’s shares rose about 10 % in pre‑market trading following the announcement. seekingalpha.com
- 6Gilead’s shares were up roughly 2.2 % after the news. rttnews.com
Open questions
- Material 2 states the total upfront payment is $90 million (cash $65 M + equity $25 M), while material 6 reports a total upfront of $135 million (cash $90 M + equity $25 M).
- Deal value is described as up to $1.9 billion in some sources and $1.88‑$1.9 billion in others, creating a range for the total potential size.
Summary written by AlphAI AI Desk from 7 of 7 sources. Not investment advice. Figures are as stated by the linked sources.